Our data demonstrated that women with high baseline CTC counts received very little survival benefit from first-line endocrine treatment, even if they were appropriate candidates for this therapy based on the hormone receptor status of their primary or metastatic tumor. The gene discussed is NR4A1; the disease is metastatic neoplasm.